vs
Pacira BioSciences, Inc.（PCRX）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Ribbon Communications Inc.的1.1倍（$177.4M vs $162.6M），Ribbon Communications Inc.净利率更高（54.8% vs 1.6%，领先53.1%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -10.3%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -8.1%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
PCRX vs RBBN — 直观对比
营收规模更大
PCRX
是对方的1.1倍
$162.6M
营收增速更快
PCRX
高出15.3%
-10.3%
净利率更高
RBBN
高出53.1%
1.6%
两年增速更快
PCRX
近两年复合增速
-8.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $162.6M |
| 净利润 | $2.9M | $89.1M |
| 毛利率 | — | 42.9% |
| 营业利润率 | 3.9% | 37.6% |
| 净利率 | 1.6% | 54.8% |
| 营收同比 | 5.0% | -10.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.07 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRBBN
| Q1 26 | $177.4M | $162.6M | ||
| Q4 25 | $196.9M | $227.3M | ||
| Q3 25 | $179.5M | $215.4M | ||
| Q2 25 | $181.1M | $220.6M | ||
| Q1 25 | $168.9M | $181.3M | ||
| Q4 24 | $187.3M | $251.4M | ||
| Q3 24 | $168.6M | $210.2M | ||
| Q2 24 | $178.0M | $192.6M |
净利润PCRXRBBN
| Q1 26 | $2.9M | $89.1M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-12.1M | ||
| Q2 25 | $-4.8M | $-11.1M | ||
| Q1 25 | $4.8M | $-26.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $-13.4M | ||
| Q2 24 | $18.9M | $-16.8M |
毛利率PCRXRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 79.5% | 53.3% | ||
| Q3 25 | 80.9% | 50.1% | ||
| Q2 25 | 77.4% | 49.6% | ||
| Q1 25 | 79.7% | 45.4% | ||
| Q4 24 | 78.7% | 55.7% | ||
| Q3 24 | 76.9% | 52.1% | ||
| Q2 24 | 75.1% | 50.8% |
营业利润率PCRXRBBN
| Q1 26 | 3.9% | 37.6% | ||
| Q4 25 | 1.2% | 4.1% | ||
| Q3 25 | 3.5% | 1.3% | ||
| Q2 25 | 4.7% | 1.9% | ||
| Q1 25 | 1.2% | -10.8% | ||
| Q4 24 | 13.2% | 13.2% | ||
| Q3 24 | -82.8% | -0.4% | ||
| Q2 24 | 15.9% | -1.0% |
净利率PCRXRBBN
| Q1 26 | 1.6% | 54.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -5.6% | ||
| Q2 25 | -2.7% | -5.0% | ||
| Q1 25 | 2.8% | -14.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | -6.4% | ||
| Q2 24 | 10.6% | -8.7% |
每股收益（稀释后）PCRXRBBN
| Q1 26 | $0.07 | $0.50 | ||
| Q4 25 | $0.05 | $0.50 | ||
| Q3 25 | $0.12 | $-0.07 | ||
| Q2 25 | $-0.11 | $-0.06 | ||
| Q1 25 | $0.10 | $-0.15 | ||
| Q4 24 | $0.38 | $0.05 | ||
| Q3 24 | $-3.11 | $-0.08 | ||
| Q2 24 | $0.39 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $419.1M |
| 总资产 | $1.2B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRBBN
| Q1 26 | $144.3M | $67.6M | ||
| Q4 25 | $238.4M | $96.4M | ||
| Q3 25 | $246.3M | $74.8M | ||
| Q2 25 | $445.9M | $60.5M | ||
| Q1 25 | $493.6M | $71.2M | ||
| Q4 24 | $484.6M | $87.8M | ||
| Q3 24 | $453.8M | $37.2M | ||
| Q2 24 | $404.2M | $64.6M |
总债务PCRXRBBN
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $342.1M | ||
| Q3 25 | $376.7M | $344.3M | ||
| Q2 25 | $580.5M | $346.5M | ||
| Q1 25 | $583.4M | $347.4M | ||
| Q4 24 | $585.3M | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益PCRXRBBN
| Q1 26 | $653.9M | $419.1M | ||
| Q4 25 | $693.1M | $449.0M | ||
| Q3 25 | $727.2M | $360.1M | ||
| Q2 25 | $757.8M | $370.4M | ||
| Q1 25 | $798.5M | $381.8M | ||
| Q4 24 | $778.3M | $404.6M | ||
| Q3 24 | $749.6M | $395.5M | ||
| Q2 24 | $879.3M | $405.0M |
总资产PCRXRBBN
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B |
负债/权益比PCRXRBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.76× | ||
| Q3 25 | 0.52× | 0.96× | ||
| Q2 25 | 0.77× | 0.94× | ||
| Q1 25 | 0.73× | 0.91× | ||
| Q4 24 | 0.75× | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
